FDA approval of a new drug is a critical milestone for pharmaceutical companies, often leading to increased investor confidence and potential market expansion. For X4 Pharmaceuticals, this approval marks a significant achievement in its product pipeline, likely to positively impact its stock price in the short term due to the expanded treatment options for WHIM Syndrome and the potential for increased sales and market penetration.